Lili Xiaoli Cheng PhD

Lili Xiaoli Cheng is a Senior Director of Translational Biology and Product Development at Anwita Biosciences, San Carlos, California, United States. She is delivering results by leading research projects, she is backed by more than 10 years of drug discovery experience across target validation, hit identification, preclinical proof-of-concept, and early-stage clinical development, focusing on developing oral peptide-based therapeutics. She utilizes excellent communication skills to unite cross-functional discovery teams on achieving research objectives through end-to-end project planning, implementing strategies and approaches, managing timelines, and allocating resources to solve complex scientific problems. Throughout her career so far, she has prepared three oral drugs for first-in-human Phase 1 clinical trials; secured a research collaboration partnership with Janssen Biotech that provided milestone payments to her organization; obtained significant funding from SBIR grants; and she is contributed to multiple publications, presentations, and patents involving oral peptide inhibitors of the interleukin-23 receptor and alpha4beta7 integrin for the treatment of patients with IBD.